Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 19/20 | 0.52 |
| ▸ | TNKS2 | Q9H2K2 | 19/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.52 |
| ▸ | PARP1 | P09874 | 11/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829722 | 0.88 | TNKS (0.57) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17829787 | 0.87 | TNKS (0.52) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17818491 | 0.86 | TNKS (0.71) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL17829731 | 0.85 | TNKS (0.54) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17829729 | 0.84 | TNKS (0.57) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17829718 | 0.84 | TNKS (0.56) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17831852 | 0.83 | TNKS (0.46) | TNKSTNKS2PARP2PARP1PIM1 | |
| SCHEMBL17829745 | 0.79 | TNKS (0.49) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17829936 | 0.78 | TNKS (0.52) | TNKSTNKS2PARP2PARP1WNT3A | |
| SCHEMBL17829743 | 0.77 | TNKS (0.47) | TNKSTNKS2PARP2PARP1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TNKS 1771/4885TNKS2 2811/4885PARP2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.